OPEN MINDS The Behavioral Health & Social Service Industry Analyst Industry News Although it has been on the market since February 1990, only about 13% of the candidates for this new anti-schizophrenic drug are getting it according to Sandoz Pharmaceuticals Corporation the developer of the medication. Courts have ruled that Medicaid should pay for the drug, but evidently budget considerations and administrative roadblocks have hampered implementation of the court orders. The National Association of Mental Health Program Directors believes that all states will eventually pay for the drug.